Inogen, Inc. (NASDAQ:INGN) Q3 2023 Earnings Call Transcript

Nabil Shabshab: And I’ll just add, Mike, the majority of the investment goes to the clinical regulatory work in terms of us securing, getting ready for filing in terms of the FDA approval.

Mike Matson: Okay. Got it. But the kind of — excluding that, you would have reiterated the prior guidance, I assume, excluding that acquisition.

Mike Sergesketter: Yes. We would have been ending probably towards the lower end of that — of the original guidance, yes.

Operator: There are no further questions at this time. And I would like to turn the floor back over to Nabil for any closing comments.

Nabil Shabshab: Okay. Thank you. Our continued focus on executing our commercial strategy includes our plan to drive adoption of our current portable oxygen concentrators while expanding our portfolio to serve the larger COPD patient population as well as extend into adjacent indications, including dyspnea and hypercapnia. We also plan to efficiently integrate Physio-Assist and pursue regulatory clearance for Simeox in the U.S. Looking ahead, we remain focused on supporting a return to revenue growth while diligently managing expenses and cash. To conclude, I would like to thank our Inogen team who are working diligently through some headwinds while remaining focused on setting the right foundation for growth in the years to come.

Their passionate focus on our patients and on fulfilling our purpose of improving patients’ lives through respiratory care is foundational to who we are and Inogen’s path forward. With that said, we thank you for your participation and conclude the call.

Operator: And this concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.